Latest Insider Transactions at Kura Oncology, Inc. (KURA)
This section provides a real-time view of insider transactions for Kura Oncology, Inc. (KURA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Kura Oncology, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Kura Oncology, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 14
2025
|
Kathleen Ford Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
6,902
-6.15%
|
$75,922
$11.18 P/Share
|
|
Nov 14
2025
|
Thomas James Doyle SVP, Finance & Accounting |
SELL
Open market or private sale
|
Direct |
4,539
-3.37%
|
$49,929
$11.18 P/Share
|
|
Nov 14
2025
|
Mollie Leoni Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
15,485
-6.43%
|
$170,335
$11.18 P/Share
|
|
Nov 14
2025
|
Brian T. Powl Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
8,887
-5.98%
|
$97,757
$11.18 P/Share
|
|
Nov 14
2025
|
Teresa Brophy Bair Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
8,804
-4.47%
|
$96,844
$11.18 P/Share
|
|
Nov 13
2025
|
Kathleen Ford Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
48,900
+30.34%
|
-
|
|
Nov 13
2025
|
Thomas James Doyle SVP, Finance & Accounting |
BUY
Grant, award, or other acquisition
|
Direct |
24,967
+15.63%
|
-
|
|
Nov 13
2025
|
Mollie Leoni Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
82,500
+25.51%
|
-
|
|
Nov 13
2025
|
Brian T. Powl Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
48,900
+24.76%
|
-
|
|
Nov 13
2025
|
Troy Edward Wilson President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
182,500
+29.83%
|
-
|
|
Nov 13
2025
|
Teresa Brophy Bair Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
48,900
+19.89%
|
-
|
|
Sep 29
2025
|
Thomas James Doyle SVP, Finance & Accounting |
SELL
Open market or private sale
|
Direct |
4,541
-3.97%
|
$36,328
$8.94 P/Share
|
|
Sep 29
2025
|
Troy Edward Wilson President and CEO |
SELL
Open market or private sale
|
Direct |
36,615
-12.92%
|
$292,920
$8.94 P/Share
|
|
Sep 29
2025
|
Mollie Leoni Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
12,314
-7.21%
|
$98,512
$8.94 P/Share
|
|
Sep 29
2025
|
Kathleen Ford Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
6,892
-9.81%
|
$55,136
$8.94 P/Share
|
|
Sep 29
2025
|
Teresa Brophy Bair Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
8,805
-5.61%
|
$70,440
$8.94 P/Share
|
|
Sep 29
2025
|
Brian T. Powl Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
8,891
-8.19%
|
$71,128
$8.94 P/Share
|
|
Sep 27
2025
|
Thomas James Doyle SVP, Finance & Accounting |
BUY
Grant, award, or other acquisition
|
Direct |
24,966
+17.92%
|
-
|
|
Sep 27
2025
|
Troy Edward Wilson President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
182,500
+39.17%
|
-
|
|
Sep 27
2025
|
Mollie Leoni Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
82,500
+32.58%
|
-
|
|
Sep 27
2025
|
Kathleen Ford Chief Operating Officer |
SELL
Grant, award, or other acquisition
|
Direct |
48,900
-41.03%
|
-
|
|
Sep 27
2025
|
Teresa Brophy Bair Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
48,900
+23.77%
|
-
|
|
Sep 27
2025
|
Brian T. Powl Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
48,900
+31.05%
|
-
|
|
Sep 08
2025
|
Troy Edward Wilson President and CEO |
BUY
Open market or private purchase
|
Direct |
50,000
+33.12%
|
$400,000
$8.2 P/Share
|
|
Aug 13
2025
|
Troy Edward Wilson President and CEO |
BUY
Open market or private purchase
|
Direct |
13,494
+20.93%
|
$80,964
$6.64 P/Share
|
|
Aug 12
2025
|
Troy Edward Wilson President and CEO |
BUY
Open market or private purchase
|
Direct |
36,506
+49.35%
|
$182,530
$5.85 P/Share
|
|
May 19
2025
|
Kathleen Ford Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,558
-6.8%
|
$9,348
$6.28 P/Share
|
|
May 19
2025
|
Teresa Brophy Bair Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,559
-1.42%
|
$7,795
$5.96 P/Share
|
|
Mar 21
2025
|
Faheem Hasnain |
SELL
Open market or private sale
|
Direct |
22,682
-48.61%
|
$181,456
$8.0 P/Share
|
|
Mar 21
2025
|
Faheem Hasnain |
BUY
Exercise of conversion of derivative security
|
Direct |
22,682
+32.71%
|
$136,092
$6.32 P/Share
|
|
Jan 28
2025
|
Thomas James Doyle SVP, Finance & Accounting |
SELL
Open market or private sale
|
Direct |
4,949
-1.35%
|
$34,643
$7.87 P/Share
|
|
Jan 28
2025
|
Brian T. Powl Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,583
-2.58%
|
$11,081
$7.87 P/Share
|
|
Jan 28
2025
|
Francis Burrows Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,166
-4.85%
|
$15,162
$7.87 P/Share
|
|
Jan 28
2025
|
Kathleen Ford Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,817
-7.84%
|
$12,719
$7.87 P/Share
|
|
Jan 28
2025
|
Teresa Brophy Bair Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
7,281
-3.2%
|
$50,967
$7.87 P/Share
|
|
Jan 28
2025
|
Mollie Leoni Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,963
-1.36%
|
$34,741
$7.87 P/Share
|
|
Jan 02
2025
|
Mollie Leoni Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
46,250
+33.16%
|
-
|
|
Jan 02
2025
|
Brian T. Powl Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
46,250
+43.02%
|
-
|
|
Jan 02
2025
|
Teresa Brophy Bair Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
46,250
+28.64%
|
-
|
|
Jan 02
2025
|
Thomas James Doyle SVP, Finance & Accounting |
BUY
Grant, award, or other acquisition
|
Direct |
42,500
+20.7%
|
-
|
|
Nov 18
2024
|
Kathleen Ford Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
526
-2.22%
|
$8,416
$16.03 P/Share
|
|
May 20
2024
|
Teresa Brophy Bair Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,615
-3.65%
|
$57,530
$22.15 P/Share
|
|
Jan 30
2024
|
Stephen Dale Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,825
-11.06%
|
$101,325
$21.55 P/Share
|
|
Jan 29
2024
|
Stephen Dale Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,158
-7.3%
|
$121,686
$17.8 P/Share
|
|
Jan 29
2024
|
Kathleen Ford Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,496
-6.48%
|
$25,432
$17.8 P/Share
|
|
Jan 29
2024
|
Teresa Brophy Bair Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,053
-2.89%
|
$34,901
$17.8 P/Share
|
|
Jan 29
2024
|
Thomas James Doyle SVP, Finance & Accounting |
SELL
Open market or private sale
|
Direct |
2,318
-1.56%
|
$39,406
$17.8 P/Share
|
|
Jan 24
2024
|
Troy Edward Wilson President and CEO |
SELL
Open market or private sale
|
Direct |
91,052
-95.95%
|
$1,821,040
$20.23 P/Share
|
|
Jan 24
2024
|
Troy Edward Wilson President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
91,052
+48.95%
|
$455,260
$5.48 P/Share
|
|
Jan 02
2024
|
Teresa Brophy Bair Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
46,250
+39.43%
|
-
|